A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Y-2 Receptor Agonist Administered Once Weekly for 4 Weeks in Subjects with Type 2 Diabetes Mellitus on a Stable Dose of Metformin.
Attachments:
 | Download Document |
